Dr Lal Pathlabs informs about board meeting

12 May 2017 Evaluate

In compliance with Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (LODR Regulations), Dr Lal Pathlabs has informed that the Board of Directors in their meeting held today, i.e. May 12, 2017, approved the Scheme of Amalgamation of Delta Ria and Pathology ( the Transferor Company), a wholly owned subsidiary of Dr. Lal PathLabs with the Company with effect from 1st April, 2017 (Appointed Date), pursuant to sections 230-232 of the Companies Act, 2013. The scheme is conditional upon and subject, to sanction of the same by the Honble National Company Law Tribunal (NCLT). As the Transferor Company is a wholly owned subsidiary of the Company, hence the Company is neither required to comply with the requirements laid under Circular No. CFD/DIL3/CIR/2017/21 dated 10th March, 2017 nor required to obtain observation letter or no objection letter from the stock exchange before filing the scheme with any Tribunal as contemplated in Circular No. CFD/DIL3/CIR/2017/26 dated 23rd March, 2017. Enclosed as Annexure A is the information pursuant to Regulation 30 of the LODR Regulations read with Circular no. CIR/CFD/ CMD/4/2015 dated 9th September, 2015.

The above information is a part of company’s filings submitted to BSE.

Dr. Lal Pathlabs Share Price

2801.95 43.30 (1.57%)
07-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Aster DM Healthcare 358.95
Apollo Hospital Ent. 6010.00
Max Healthcare Inst 822.20
Narayana Hrudayalay 1266.75
Dr. Lal Pathlabs 2801.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.